Loading stock…

Bayer Aktiengesellschaft (BAYN) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

BAYNBayer Aktiengesellschaft

Revenue FY25$53.5B

GROWTH RATING↗

VERY WEAK12 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-0%3

Revenue, next 1Y-4%2

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+2%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+6%5

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to grow around 2%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 88% of companies worldwide.

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 2%/yr, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

BAYNBayer Aktiengesellschaft

Total return Current−34.7%

Price return Current−52.8%

MOMENTUM RATING↗

WEAK31 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-11%2

3-month return-12%3

YTD return+19%7

MID & LONG-TERM▾SCORE

% of 52-week high82%6

1-year return+60%9

3-year return+1%3

5-year return-0%4

MOMENTUM ASSESSMENT

STRENGTHS

It's up 60% over the past year, but 18% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+19%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+0.5% over three years and -0.1% over five), behind 60% of the market.

The stock is underperforming over the past month (-11%) and over three months (-12%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Bayer. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

BAYNBayer Aktiengesellschaft

Revenue FY25$53.5B

GROWTH RATING↗

VERY WEAK12 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-0%3

Revenue, next 1Y-4%2

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+2%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+6%5

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to grow around 2%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 88% of companies worldwide.

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 2%/yr, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

BAYNBayer Aktiengesellschaft

Total return Current−34.7%

Price return Current−52.8%

MOMENTUM RATING↗

WEAK31 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-11%2

3-month return-12%3

YTD return+19%7

MID & LONG-TERM▾SCORE

% of 52-week high82%6

1-year return+60%9

3-year return+1%3

5-year return-0%4

MOMENTUM ASSESSMENT

STRENGTHS

It's up 60% over the past year, but 18% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+19%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+0.5% over three years and -0.1% over five), behind 60% of the market.

The stock is underperforming over the past month (-11%) and over three months (-12%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Bayer. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Bayer Aktiengesellschaft

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Bayer. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Bayer. Get the full investment case.

Premium